Collaboration
New Test Offers Greater Accuracy in Early Detection of Colorectal Cancer
Results of two studies suggest that a new, investigational colorectal cancer screening test developed in a collaboration between Mayo Clinic and Exact Sciences Inc. (Madison, WI) is highly accurate and significantly more sensitive than other noninvasive tests at detecting precancerous tumors (adenomas) and early-stage cancer. The first study, to be published in the February issue of Gastroenterology, shows that a new multi-marker stool DNA test is highly accurate at detecting precancerous...
Roche, Technoclone Enter into Strategic Alliance
Roche has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria. The alliance complements Roche’s strategic re-focus on hemostasis. Following the discontinuation of the distribution agreement with STAGO1 and the recent acquisition of Verum Diagnostica, Roche will bring to market a brand-new, innovative hemostasis portfolio including two new system families, platelet function testing and a new holistic...
Tecan, Waters Sign OEM Agreement
The Tecan Group announced an OEM agreement with Waters Corp. Under the agreement, Tecan will supply instruments for the sample preparation of Waters’ clinical laboratory assays. The instrument is based on Tecan’s Freedom EVO liquid handling platform and will be used as a component of the Waters system in combination with a Waters ACQUITY TQD liquid chromatograph/mass spectrometer (LC/MS/MS). Tecan expects to start the commercial supply of instruments within the next six months....
Ventana, Bayer to Collaborate on Companion Diagnostic for Cancer Therapy
Ventana Medical Systems Inc., a member of the Roche Group, has entered into a strategic collaboration agreement with Bayer Bayer Pharma AG (Bayer) to develop a molecular companion diagnostic test intended to identify patients most likely to benefit from a Bayer antibody-drug conjugate (ADC). Ventana’s diagnostic immunohistochemistry platform aims to analyze the expression level of certain tumor targets serving as biomarkers in clinical studies for patient selection. This will support the...
Life Technologies, DaAn Gene to Develop Molecular Diagnostic Assays in China
Life Technologies Corp. has signed an agreement with DaAn Gene, a Chinese company in molecular IVDs, to form Life Technologies DaAn Diagnostics, a joint venture diagnostics business in China. The move is expected to contribute to the early diagnosis of oncology, infectious diseases and genetic diseases. Financial terms of the deal were not disclosed. Life Technologies DaAn Diagnostics, with its headquarters in Guangzhou, will develop and commercialize a portfolio of molecular diagnostic assays...
Ventana to Collaborate with Pfizer, CST on Lung Cancer Companion Diagnostic
Ventana Medical Systems Inc., a member of the Roche Group, has entered into a collaboration agreement with Pfizer Inc. and a license agreement with Cell Signaling Technology (CST) to develop the first fully automated and standardized immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements. Ventana will develop the test which is intended to identify non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who...
Qiagen, Max Planck Institute for Infection Biology to Develop TB Assay
Qiagen NV and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime. Financial terms were not disclosed. As a follow-up to those who test positive for latent TB, this new test will be designed to enable early treatment before reactivation of the TB disease, when it becomes...
Syndax Pharmaceuticals, Ventana Medical Systems to Develop Companion Diagnostic Test for Lung Cancer
Syndax Pharmaceuticals Inc. and Ventana Medical Systems Inc. have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax’s proprietary lead molecule entinostat. “Syndax is pleased to partner with Ventana, a world leader and innovator of tissue-based diagnostic solutions for patients worldwide, as we advance the development of entinostat in NSCLC,” said Joanna Horobin,...
ZyGem, USAMRIID to Develop Sample Processing for Biothreat Agents
ZyGem Corp. and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) announced the signing of a Cooperative Research and Development Agreement (CRADA) for the development of simplified sample processing solutions for biothreat agents. The two organizations will collaborate on the development, testing and validation of new solutions for the rapid and efficient extraction of DNA and other nucleic acids for the detection of biothreat agents and other pathogens from a variety...
Sony DADC, Axela to Develop Consumables for Assays
Sony DADC and Axela announced a collaboration to develop and manufacture smart consumables for the dotLab mX detection system. The dotLab mX System combines automated flow processing with diffractive optics to enable real time detection of binding events and full characterization of biomarkers through sequential probing. This provides significant analytical advantages for multiplex assay development and routine analysis in clinical research and diagnostics.  Paul Smith, Axela’s COO,...